Systemic treatment advanced recurrent endometrial carcinoma current status future directions Multiple systemic therapies patients endometrial cancer progestins standard initial treatment metastatic disease past years effective patients several large trials benefit adjuvant setting Alternative agents tamoxifen modest activity Few studies combinations active drugs Doxorubicin cisplatin active cytotoxic agents current randomized study combination drugs single-agent doxorubicin effectiveness drugs hematopoietic growth factors alternative hormonal cytotoxic agents sound scientific rationale effective treatment options patients 